Compass, Inc. Share Price Target ‘$4.15’, now -4.2% Downside Potential

DirectorsTalk Interviews

Compass, Inc. which can be found using ticker (COMP) have now 9 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The target price High/Low ranges between $6.00 and $3.00 calculating the mean target share price we have $4.15. (at the time of writing). Given that the stocks previous close was at $4.33 this would imply there is a potential downside of -4.2%. It’s also worth noting that there is a 50 day moving average of $3.56 while the 200 day moving average is $3.18. The market cap for the company is 2.13B. The stock price for Affirm Holdings, Inc. is $4.30 USD

The potential market cap would be $2,037,923,773 based on the market consensus.

The company has a dividend yield of 5.95%. Other points of data to note are a P/E ratio of -, revenue per share of $10.46 and a -10.37% return on assets.

Compass, Inc. is a technology-enabled brokerage that provides an end-to-end platform of software, services, and support to helps its residential real estate agents to deliver service to seller and buyer clients. The Company’s platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service, brokerage services and other critical functionalities, all custom-built for the real estate industry and enables its core brokerage services. The platform also uses data, analytics, artificial intelligence and machine learning to deliver recommendations and outcomes for Compass agents and their clients. Agents use its platform to assist home sellers and buyers in listing, marketing, selling and finding homes, as well as through the provision of services, such as title, escrow and mortgage. Its Glide tools include completion of various real estate forms, offers preparation, as well as e-signature and collaboration capabilities.

Share on:

Latest Company News

EDX Medical raises £2.7m to expand employee health screening service

EDX Medical has raised approximately £2.7m through a share subscription to support the expansion of its employee health screening service, as discussions progress with several major UK employers.

GSK gains priority FDA review for Jemperli in rectal cancer

GSK says the US FDA has accepted Jemperli for priority review in previously untreated stage II and III locally advanced rectal cancer.

Cora Gold secures interim renewal of Sanankoro II exploration permit

Cora Gold has secured the first interim renewal of the Sanankoro II exploration permit in south Mali as it progresses towards full permitting.

Likewise Group completes purchase of Corby distribution hub

Likewise Group plc has completed the freehold acquisition of a new Corby distribution hub for £9.57 million, with operations expected from January 2027.

Adaptix secures US Federal sales channel for Ortho350

Adaptix has secured a dedicated US federal sales channel for the Ortho350 through an exclusive reseller agreement with Spartan Medical.

MERLYN broadens ARYSTO range with new stone shower tray

MERLYN is expanding its premium ARYSTO range with ARYSTO Stone, a new shower tray launching in October 2026 with a focus on design, safety and practicality.

    Search